Skip to content Skip to footer
Subscribe Now
TOP 20

Top 20 Generic Companies of 2026 

Shots:   Sandoz, Sun Pharma, and Shanghai Fosun Pharma emerged as the leading generic pharmaceutical companies in 2026, with 2025 revenues of $11.08B, $6.55B, and $5.92B, respectively. Strong demand for biosimilars, continued portfolio expansion, new product launches, and broader access to affordable medicines supported growth across the leading companies The global generics landscape continues to evolve…
3 days ago

Read more

NEWS

Zydus to Acquire Assertio in ~$166.4M All-Cash Deal

Shots: Assertio Holdings’ Board has approved a definitive agreement with Zydus Worldwide DMCC, a subsidiary of Zydus, to acquire all outstanding Assertio shares, delisting it from the Nasdaq Assertio’s Board determined Zydus’ proposal constituted a “Superior Proposal” under the Garda merger agreement & authorized termination of the Garda transaction As per the deal, Zydus will…
May 14, 2026

Read more

NEWS

Formycon Receives the US FDA Approval for Nufymco (Biosimilars, Lucentis)

Shots:  The US FDA has approved Nufymco (ranibizumab-leyk), an interchangeable biosimilar of Lucentis, with Zydus serving as its commercialization partner in the US  Nufymco is an interchangeable Lucentis biosimilar developed by Formycon, approved for the treatment of wet AMD, diabetic macular edema, diabetic retinopathy, retinal vein occlusion-related macular edema, and myopic choroidal neovascularization  Zydus secured exclusive US and Canada rights to Formycon’s Keytruda…
December 23, 2025

Read more

NEWS

Formycon Partners with Zydus to Commercialize FYB206 (Biosimilar, Keytruda) in the US and Canada

Shots: Formycon has entered into an exclusive licensing & supply agreement with Zydus Lifesciences Global FZE, UAE (Zydus' subsidiary) to commercialize Formycon’s FYB206, a biosimilar version of Merck’s Keytruda (pembrolizumab), in the US & Canada As per the deal, Formycon will be responsible for development, registration, manufacturing & supply of the product, while Zydus Lifesciences…
December 10, 2025

Read more

TOP 20

Top 20 Generic Pharma Companies of 2025 

Shots:  Generic medicines play a pivotal role in offering cost-effective alternatives to high-priced pharmaceuticals. They often serve as a critical lifeline in developing and underdeveloped nations, helping to address both chronic and infectious diseases.  In 2024, the global generics market was valued at $445.62B, with projections to reach approximately $468.08B in 2025 and ~$728.64B by…
October 8, 2025

Read more

NEWS

Zydus Reports Topline P-IIb/III (EPICS-III) Trial Data of Saroglitazar for Primary Biliary Cholangitis (PBC)

Shots: Zydus has reported topline P-IIb/III (EPICS-III) trial results in PBC pts resistant or intolerant to ursodeoxycholic acid (UDCA), where pts were randomized to Saroglitazar (1mg) or PBO, following optimal dose selection Trial met its composite 1EP, showing a 48.5% treatment difference in biochemical response, & also achieved its key 2EP with a higher proportion…
September 1, 2025

Read more